×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal
Morningstar
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal ... AbbVie said the Food and Drug Administration had fully approved its ovarian...
1 month ago
Inside AbbVie's $10B buyout of ImmunoGen—and the bidding war it swooped in on
Fierce Pharma
AbbVie is entering 2024 with a foothold in the antibody-drug conjugate (ADC) field thanks to its late-2023 buyout of ImmunoGen worth more...
3 months ago
AbbVie seeks lift from 'guided missile' cancer drug with $10 bln ImmunoGen deal
Reuters
AbbVie will buy ImmunoGen for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to acquire a maker of promising "guided...
5 months ago
AbbVie Cuts Its Guidance on ImmunoGen Deal
Investopedia
Key Takeaways · AbbVie reduced its current quarter outlook related to costs from its acquisition of ImmunoGen. · The drug maker announced the...
2 months ago
AbbVie concludes acquisition of ImmunoGen for $10.1bn
Pharmaceutical Technology
AbbVie has completed the acquisition of ImmunoGen for $10.1bn, a move that significantly bolsters its oncology pipeline.
2 months ago
Ropes & Gray Represents ImmunoGen in its $10.1 Billion Sale to AbbVie | News & Events
Ropes & Gray LLP
Ropes & Gray Represents ImmunoGen in its $10.1 Billion Sale to AbbVie ... Ropes & Gray represented ImmunoGen in its sale to AbbVie, which will...
5 months ago
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
CNBC
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion · Biotech stocks rose as AbbVie announced plans to buy...
5 months ago
AbbVie to Buy Cancer Biotech ImmunoGen for More Than $10 Billion
WSJ
AbbVie to Buy Cancer Biotech ImmunoGen for More Than $10 Billion · The deal is a new bet by a big pharmaceutical company on a promising novel...
5 months ago
Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against mpox virus
Nature
Two MPXV antigens, M1 and A35, were used to develop a 'two-in-one' version of the chimeric immunogen, which we named DAM (in tandem fusion of...
3 months ago
AbbVie Buys ImmunoGen in $10B Deal, Gains Access to ADC for Ovarian Cancer
BioSpace
Facing the loss of Humira revenues from biosimilar competition, AbbVie is looking to grow its pipeline by acquiring ImmunoGen and its...
5 months ago